Skip to main content
Premium Trial:

Request an Annual Quote

CuraGen, Gemini in Target Discovery Collaboration

Premium

C

AMBRIDGE, UK--Gemini Genomics, formerly Gemini Holdings, announced that it has entered into a two-year drug target identification collaboration with CuraGen to accelerate drug discovery. CuraGen and Gemini scientists will work together to associate CuraGen's thousands of single-nucleotide polymorphisms with disease traits derived from Gemini's database of clinical populations.

Gemini changed its name late last month to reflect its clinical genomics approach to identifying disease genes.

Separately, CuraGen expanded its drug discovery and pharmacogenomics collaboration with COR Therapeutics of South San Francisco. The companies will use CuraGen's PathCalling proteomics technology and bioinformatics systems to create an annotated database of protein-protein interactions derived from cardiovascular endothelial cells.

Filed under

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.